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OBJECTIVE: There are no doubts about the clinical benefits of treatment with GnRH analogs for patients
diagnosed with central precocious puberty (CPP). However, laboratory monitoring of CPP is still a matter of
considerable controversy in the literature. Therefore, the main objective of this study was to evaluate the cut-off
values of stimulated LH that determine gonadotrophic suppression.
METHODS: Twenty-four girls, on treatment with leuprorelin acetate (LA) at 3.75 mg IM every 28 days, were
studied. The clinical parameters used to indicate clinical effectiveness were regression or maintenance of sexual
characteristics according to the Tanner stage, growth velocity reduction, reduction or maintenance of the
difference between bone age and chronological age and maintenance or improvement of the final height
prediction. For the laboratory effectiveness test, basal estradiol, LH, and FSH levels were collected before and
1 and 2 h after the administration of 3.75 mg LA.
RESULTS: Eleven girls showed improvement in all clinical parameters, and their effectiveness tests were
compared to those of the other patients to calculate the cut-off values, which were p3.64 IU/L (p=0.004*) for
LH after 1 h and p6.10 IU/L (po0.001*) for LH after 2 h.
CONCLUSION: The LH response after the LA stimulation test, associated with clinical data and within a context
of CPP, constitutes a reliable and feasible resource and can assist in monitoring the effectiveness of treatment.
KEYWORDS: Gonadotropin-Releasing Hormone; Puberty; Therapeutics; Luteinizing Hormone; Follicle Stimulat-
ing Hormone; Estradiol; Growth.
’ INTRODUCTION
Precocious puberty (PP) is classically defined as the
development of secondary sexual characteristics before eight
years of age in girls and before nine years of age in boys (1,2).
Central precocious puberty (CPP) is a relatively rare con-
dition that can interfere with somatic (3-5) and psychosocial
(6-11) development in affected children. The current treat-
ment of choice for CPP consists of the administration of
depot GnRH analogs (GnRHa). These analogs’ clinical effec-
tiveness has been demonstrated by several authors and
includes final height improvement, regression of sexual
characteristics according to Marshall and Tanner’s classifica-
tion, decrease in growth velocity, and decrease in bone age
(BA) advancement (3,4,12-17), as well as delaying the age of
menarche (18-20). Thus, treated children develop puberty at
a similar time as their peers.
Although the treatment clinical parameters seem highly
clear, they are subjective and depend on the examiner. There-
fore, many authors indicate the need for a laboratory effec-
tiveness test that can more accurately determine gonadotropic
axis suppression (12-15,20).
The classic CPP treatment monitoring test consists of col-
lecting basal LH and FSH every 30 minutes (up to 120 minutes)
after the intravenous (IV) administration of synthetic GnRH
(12,21-22). In addition to being time consuming, expensive
and requiring venous access, the acquisition of synthetic
GnRH has become highly difficult, especially for services
within the Brazilian Unified Health System (SUS).
Another piece of data that generates controversy in the lite-
rature is the cut-off value of stimulated LH, which indicates
pubertal suppression. Several authors using different labora-
tory methods have suggested different cut-off values (12-15,20).
Therefore, the primary objectives of this study were to
evaluate the clinical and laboratory effectiveness of GnRHa
treatment for CPP and to determine cut-off values for the
hormones measured in the GnRHa test, which determine
gonadotropic suppression.DOI: 10.6061/clinics/2019/e1205
Copyright & 2019 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on February 11, 2019. Accepted for publi-
cation on August 26, 2019
1
ORIGINAL ARTICLE
’ MATERIALS AND METHODS
This study was approved by the Research Ethics Commit-
tee of Universidade Federal do Triângulo Mineiro (UFTM).
Data collection was only carried out after the term of assent
was read and the free and informed consent form was signed
by the parent/legal guardian of the children participating in
the study.
The inclusion criteria were girls with clinical aspects of
CPP, whose diagnosis was confirmed by the classic GnRH
stimulation test or by a GnRHa test and who would be
treated with depot GnRH analogs, intramuscularly, adminis-
tered every 28 days (19-23). Patients with peripheral PP were
excluded, as were patients with other endocrinopathies or
systemic diseases that would interfere with the results. On
the basis of these criteria, 24 girls followed at the Department
of Endocrinology Outpatient Clinic of UFTM were enrolled.
A clinical diagnosis of CPP was considered if the patient
had at least two of the following aspects: progression of
sexual characteristics according to Marshall and Tanner (23),
advanced BA and growth velocity over 6 cm/year. The age
of diagnosis was 6.9±1.2 years.month (yr.mo) [4.1-7.10].
Thelarche was the first sexual characteristic to appear in 23/
24 girls between 3.6 and 7.5 yr.mo, with a delay in diagnosis
ranging from 5 to 32 months. The patients also had growth
velocity increase and BA advancement evaluated by Greu-
lich and Pyle’s method (24).
Patients had a diagnosis of CPP confirmed by the classic
acute GnRH stimulation test (n=12) by IV infusion of 100 mg
of gonadorelin (Relefacts, Sanofi, Germany) or by a GnRHa
test (n=12) via IM administration of 3.75 mg of LA
(Lectrums, Sandoz from Brazil, Cambé/Pr, Brazil), which
is not a standard of diagnosis, after the acquisition of
synthetic acute GnRH became difficult. The cut-off values for
the LH peak during the tests used as indicative of activation
of the gonadotrophic axis were 3.3 IU/L and X10 IU/L
according to previous studies performed in the same service
(25,26) and in the literature, respectively (12,20). After diag-
nosis of CPP, the patients had been treated or were under-
going treatment with an intramuscular (IM) injection of
leuprorelin acetate (LA) at the initial dose of 3.75 mg every
28 days (15-20).
Regarding the etiology, all of the children had normal
pituitary imaging via nuclear magnetic resonance. In 22
cases, the CPP was considered idiopathic. However, in two
cases, periventricular arachnoid cysts with enlarged lateral
ventricles were found, and the PP was considered organic.
However, there were no pituitary hormone deficiencies of
consequence.
The study participants were assessed in the beginning
and during treatment at a time close to the effectiveness test
performance. The clinical parameters of treatment effec-
tiveness evaluated were regression or maintenance of the
pubertal stage according to Tanner (23), decrease in growth
velocity, reduction or maintenance of the difference between
BA and chronological age (CA) (DBA-CA) and improvement
of the final height prediction.
The effectiveness test was performed by measuring LH
and FSH before and 1 and 2 h after LA administration at a
dose of 3.75 mg IM. The variation between the lowest and
the highest LH values (DLH) and the LH/FSH ratio at
all moments of the test were also assessed. The stimulated
LH cut-off value considered to be indicative of gonadal
suppression, used until then in the outpatient clinic, was
o6.6 IU/L, as suggested by Brito et al. (12). To determine
new cut-off values for effectiveness testing, the analyses
performed in girls who showed improvement of all clinical
parameters were compared to the others. Moreover, the
hormone levels measured at different test moments were
compared to each other to assess the need to extend the test
up to 2 h.
To verify whether the hormone levels measured in patients
suppressed by the treatment reached prepubertal values,
a control group was selected, consisting of 11 patients followed
due to isolated precocious thelarche (n: 10) or isolated
precocious pubarche (n: 1), who were considered ‘‘variants of
normal’’ but shared the same phenotype and in whom a
laboratory diagnosis of CPP was ruled out. Each variable
studied in the effectiveness test of the girls undergoing
treatment (and suppressed) was compared with the variables
measured in the stimulation test of the control group patients
(performed to rule out CPP).
LH and FSH were measured using Elecsys Assay
commercial kits (Roche Diagnostics GmbH, Mannheim,
Germany) according to the electrochemiluminescence method
(ECLIA) and analyzed in a Cobas 6000 and 601 automated
system (Roche Diagnostics, Mannheim, Germany). The mini-
mum detection value of the method is 0.1 IU/L for both
hormones. LH has inter- and intra-assay variabilities of
approximately 2% each. FSH has an interassay variability of
up to 4.5% and intra-assay variability of up to 2.8%. Estradiol
was also measured using the Elecsys Estradiol III Assay
(Roche Diagnostics GmbH, Mannheim, Germany) through
ECLIA and analyzed by the same automated system as the
above mentioned hormones. The method’s lower limit value
is 18.36 pmol/L, and its intra- and interassay variability
values are up to 6.7% and 10.6%, respectively.
Statistical Analysis
The data are presented as the mean ± SD and range.
Normal distribution was analyzed using the Shapiro-Wilk
test, and for comparisons of two independent samples (such
as basal and stimulated LH and FSH during treatment vs the
same parameters of the normal control group), the Mann-
Whitney test was used. To determine the levels of gonado-
tropic suppression, a receiver operating characteristic (ROC)
curve analysis was performed for each test variable when
testing the treatment effectiveness. Anthropometric clinical
data obtained after six months of treatment with GnRHa
were considered the ‘‘gold standard’’, and controlled vs un-
controlled patients were evaluated. The sample size for the
ROC curve was obtained according to Arango (27) and
calculated with the aid of DIMAM 1.0 software. (Guanabara
Koogan, Rio de Janeiro, RJ, Brazil, version 2005).
To establish whether it was actually necessary to perform
the hormone measurements 2 h after the GnRHa testing, the
hormone levels measured at the different moments were
compared using Friedman’s test. Comparisons and data
from the ROC curve analysis were obtained using SPSS
version 20 and Medcalc 10.3 software, respectively. The
observed differences were considered significant when the
significance level (p) was less than 0.05.
’ RESULTS
At the start of treatment, the girls’ mean CA was 7.8±1.4
years.month (yrs.mo). The mean BA was 9.11±1 yrs.mo
(4.5-9.5). The DBA-CA at the start of treatment was, on
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average, 25.2±15.1 (-19-53). The mean growth velocity (GV)
at the start of treatment was 9.0±3.24 cm/year (3.0 to 18.0 cm/
year). Auxological parameters at diagnosis and during treat-
ment are represented in Table 1.
All of the patients were treated with a standard dose of
3.75 mg depot LA (Lectrums, Sandoz) IM every 28 d; the
initial dose per weight was 130.0±49.7 mg/kg and ranged
from 70.5 to 292.9 mg/kg. To determine whether LA treat-
ment was effective, the gonadotropin-stimulation test was
performed. At that time, the patients’ clinical characteristics
were studied. The mean time between the start of treatment
and the effectiveness test performance was 10.3±4.8 months.
The mean CA was 8.9±1 yr.mo, whereas the mean BA was
11.1±1.4 yr.mo. The mean DBA-CA was 26.5±17.6 yr.mo
(Table 1).
At the reassessment, the mean LA dose according to the
patients’ weights decreased to 111.8±38.7 mg/kg (from 66.7
to 234.4 mg/kg). Individualized clinical and laboratory data
aimed to determine treatment effectiveness are presented
in Table 2. To calculate GV prior to reassessment, the last
6-month period of treatment was considered in most of
the patients, and it was found that the mean GV decreased to
6.0±2.3 cm/year and the GV standard deviation to 0.6±2.6.
Eight patients (30%) did not attain initial assumed adequate
laboratory suppressed criteria (o6.6 IU/L) (Table 2), which
could be due either to lack of adherence or the need for a
large dose of LA. After ensuring that the children were
receiving their medication regularly, it was adjusted by
reducing the interval between doses to 21 d, considering that
this option was the one available in Brazilian Public Services.
Another question raised by the present study was whether
it would be necessary to extend the test with GnRHa up to
2 h. Hormone measurements were compared to each other at
different test moments, and it was found that basal LH
values showed significant differences between LH values
after 1 h and after 2 h of testing (po0.001*). There was no
significant difference between LH values after 1 h and LH
after 2 h of testing (p=0.164). Conversely, the values of the
FSH and LH/FSH ratio found in the effectiveness test
differed from each other (po0.001* between FSH times and
po0.001* for LH/FSH ratio times).
Basal estradiol values in patients with pubertal suppres-
sion werep18.36 pmol/L with a sensitivity (S) of 91.7% and
specificity (Sp) of 50.0% (p=0.032*). LH values after 1 h of
Table 1 - Clinical and laboratory data from children with PP.
Clinical data At the diagnosis During treatment Control group
N 24 24 11
CA (years) 6.9±1.2 (4.1–7.10)y 8.9±1.3 (5.8–10.4) 6.2±1.2 (3.2–7.4)
Height Z-score 0.85±1.25 (-2.04–3.13) 1.04±1.15 (-1.45–3.25) 0.89±0.85 (-0.68–2.16)
BMI Z-score 0.72±1.36 (-2.55–2.89) 0.91±1.39 (-1.97–3.31) 1.46±1.67 (-1.10–4.69)
BA (years) 9.0±1.8 (5.9–11.0) 11.1±1.4 (8.0–13.0) 7.4±2.3 (3.6–11.0)
DBA-CA (years) 2.0±1.3 (-1.7–3.8) 2.2±1.5 (-1–7.3) 1.4±1.3 (0.2–3.8)
GV (cm/year) 9.3±2.3 (3.0–18.0) 6.0±2.3 (1.8–11.0) 7.4±2.3 (5.8–11.16)
GV-SD 4.0±3.3 (0.3–14.1) 0.6±2.6 (-4.4–6.2) 1.8±2.6 (-0.4–6.0)
Basal estradiol (pmol/L) 20.41±13.14 (4.00–63.14) 30.18±37.26 (18.36–196.03)a 22.14±9.07 (18.36–46.99)a
Basal LH (UI/L)# 4.86±3.10 (0.23–9.67) 1.28±2.05 (0.10–7.83)b 0.12±0.11 (0.01–0.44)b
LH after 1 h (UI/L)# 32.05±21.38 (3.81–67.79) 6.96±9.83 (1.50–44.37)c 1.66±0.80 (0.35–2.66)c
LH after 2 h (UI/L)# 27.17±14.75 (6.84–49.88) 10.09±18.17 (0.90–80.14)d 2.04±0.87 (0.40–3.34)d
D LH# 28.25±19.15 (6.61–64.21) 9.04±16.45 (1.13–74.18)e 1.86±0.99 (0.25–3.24)e
Basal FSH (UI/L)# 6.41±2.23 (2.89–9.93) 2.24±1.88 (0.32–7.41)f 1.82±1.05 (0.18–3.45)f
FSH after 1 h (UI/L)# 14.54±5.44 (6.13–25.58) 5.57±3.76 (1.13–16.76)g 8.98±4.85 (1.76–19.88)g
FSH after 2 h (UI/L)# 15.81±13.86 (10.25–24.97) 8.46±6.12 (1.24–25.15)h 14.04±5.77 (2.38–25.48)h
Basal LH/FSH# 0.73±0.35 (0.24–1.32) 0.49±0.56 (0.04–2.22)i 0.12±0.15 (0.01–0.55)i
LH/FSH after 1 h# 2.00±0.95 (0.62–3.50) 1.34±1.12 (0.41–4.32)j 0.22±0.13 (0.05–0.54)j
LH/FSH after 2 h# 1.65±0.61 (0.67–2.82) 1.06±0.96 (0.36–3.52)k 0.18±0.11 (0.03–0.43)k
N: number of patients; CA: chronological age; BMI: body mass index; BA: bone age; DBA-CA: difference between bone age and chronological age; GV:
growth velocity; GV-SD: growth velocity - standard deviation; #: during the LA test; D LH: difference between the highest and the lowest measured LH
value; y: numbers expressed as the mean ± SD (minimum – maximum values).
Mann-Whitney test: letters overwritten in data pairs indicate that they were compared; only h: p40.05.
Table 2 - Cut-off values of the studied variables in the effectiveness test with LA indicating laboratory suppression.
Variable Cut-off value Sensit. (%) 95% CI Specif. (%) 95% CI AUC p
Basal E2# p5.00 91.7 61.5-99.8 50.0 21.1-78.9 0.694 0.0318*
Basal LHy p0.35 75.0 42.8-94.5 66.7 34.9-90.1 0.625 0.3292
LH after 1 h p3.64 91.7 61.5-99.8 75.0 42.8-94.5 0.799 0.0038*
LH after 2 h p6.10 100 73.5-100.0 66.7 34.9-90.1 0.840 o0.0001*
D LH p6.00 100 73.5-100.0 58.3 27.7-84.8 0.854 o0.001*
Basal FSHy p2.94 100 73.5-100.0 41.7 15.2-72.3 0.667 0.1772
FSH after 1 h p5.43 83.8 51.6-97.9 75.0 42.8-94.5 0.750 0.0236*
FSH after 2 h p8.31 83.3 51.6-97.9 75.0 42.8-94.5 0.785 0.0042*
Basal LH/FSH p0.27 83.3 51.6-97.9 58.3 27.7-84.8 0.618 0.3635
LH/FSH after 1 h p2.02 91.7 61.5-99.8 33.3 9.9-65.1 0.573 0.5523
LH/FSH after 2 h p0.89 83.3 51.6-97.9 50.0 21.1-78.9 0.632 0.2681
#: E2: expressed in pmol/L; y: LH and FSH: expressed in UI/L; Sensit.: sensitivity; Specif.: specificity; AUC: area under the curve; h: hour; 95% IC: 95%
confidence interval; *po0.05.
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testing showed a cut-off value of p3.64 IU/L (S: 91.7% and
Sp: 75.0%; p=0.038*), while LH after 2 h of testing showed a
cut-off valuep6.10 IU/L (S: 100% and Sp: 66.7%; po0.001*),
which is represented in Figure 1.
The DLH showed a cut-off value p6 IU/L (S: 100% and
Sp: 58.3%; po0.001*). FSH also showed statistical signifi-
cance for its stimulated levels, and its cut-off value after 1 h
of testing was p5.43 IU/L (S: 83.8% and Sp: 75.0%;
p=0.024*), and after 2 h of testing, this value was p8.31
IU/L (S: 83.3% and Sp: 75.0%; p=0.042*). The other variables
studied in the test were not statistically significant. Table 3
shows the cut-off values for the effectiveness test.
Finally, to evaluate whether the patients with a CPP
diagnosis who showed improvement in all assessed clinical
parameters had hormone values after the stimulation test
with GnRHa that were as low as those in the control group,
each test variable of these two groups was compared
between them. Except for basal estradiol and basal FSH, all
other variables showed significant differences between the
groups. Table 4 shows these results.
’ DISCUSSION
There are no doubts regarding the need for CPP treatment
with GnRHa and its clinical effectiveness (1-20). However,
the laboratory monitoring of CPP treatment still generates
controversy in the literature, specifically with regard to LH
concentrations indicating the cut-off value that would define
suppression of the hypothalamus/pituitary axis, which in
association with an expected behavior of clinical parameters
would convey the effectiveness of the treatment. In our study
involving 24 girls with CPP and employing ECLIA as a
method to assay hormonal concentrations, we identified
values of LHp3.64 UI/L at the first hour andp6.10 UI/L at
the second hour of the depot LA stimulation test as cut-
off values that would reliably indicate suppression of the
hypothalamus/pituitary axis. Unfortunately, we could not
compare these figures with the ‘‘gold standard’’ test using
synthetic GnRH, which is used to determine gonadotropic
axis activation. Conversely, we had the opportunity to com-
pare our data with those from a natural control group (26) of
11 girls with isolated premature thelarche, who, in general,
shared clinical and laboratory similarities with prepubertal
children.
Despite, as previously mentioned, the subjectivity of the
clinical parameters related to puberty treatment follow-up, it
was necessary to use the clinical examination as the basis for
calculating gonadal hormone suppression cut-off values,
since synthetic GnRH employed to test the LH response
and monitor treatment became unavailable. To increase the
accuracy of this examination, each patient was assessed at
each consultation by three experienced pediatric endocrinol-
ogists who always reached a consensus on the Tanner stage.
They also jointly assessed the patients’ BA by X-ray. At
each consultation, the height of the patients was measured
three times, and the average of the three measurements was
used. In addition to careful clinical examination, clinical
improvement with treatment was considered only when all
clinical parameters (Tanner stage, GV, difference between BA
and CA, and final height prediction) improved or did not
worsen.
Several different cut-off levels of LH after the LA test
have been reported in the literature and have shown great
variations related to the LH assays and the time of sampling
(12,21,28,29). In fact, there is no clear cut-off for the diagnosis
of CPP or for the monitoring of GnRH treatment (30).
Brito et al. (12), on the basis of 16 clinically well-
suppressed girls with CPP by a standard 3.75 mg of LA,
defined the cut-off LH concentration as o6.6 IU/L 2 h after
GnRHa injection. Despite using the fluoroimmunometric assey
(FIA) method, this cut-off is closest to ours at 2 h. Dermibilek
et al. (30) in a larger sample of 142 girls well-controlled by a
Figure 1 - ROC curves of LH levels measured at 1 h (A) and 2 h (B) after intramuscular administration of 3.75 mg LA (GnRH analog test).
AUC: Area Under the Curve.
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standard depot LA treatment comparable to ours and using
FIA, the method closest to ECLIA, reported a cut-off of 2.5
IU/L. However, these researchers chose to sample a single
LH measurement at 90 minutes. The researchers reported
concordance between these values and those derived from the
classic acute GnRH stimulation test, although the LH peak in
this test occurs in general at 60 minutes (25). Perhaps our
differences in suppression were due to the time chosen for
sampling because our numbers at 1 h were close to those found
at 90 minutes, and the ROC curves reported by Dermibilek
et al. (29) showed the best sensitivity and specificity probably
related to the largest number of patients. Our LH values of
p3.64 IU/L after 1 h of testing and p6.10 IU/L after 2 h of
testing showed good sensitivity and specificity in addition to
statistical significance. These values are close to those sug-
gested in the literature, corresponding to 4.0 IU/L after
40 minutes of testing (13) and 6.6 IU/L after 2 h of testing (12).
DLH values were not higher than 6.00 IU/L in suppressed
patients, but DLH should be used with caution as a para-
meter of treatment monitoring because it is not reproducible.
In relation to the time of sampling, Bhatia et al. (21)
demonstrated that LA, despite being a depot and extended-
release medication, has free particles in its preparation and
can stimulate gonadotropin release 7.5 minutes after its
administration. The LH peak is sustained between 30 and
120 minutes, and a single measurement during that interval
is sufficient to represent its maximum level after leuprorelin
administration. Conversely, FSH levels show a progressive
increase up to 120 minutes after administration (21). Follow-
ing this line of reasoning, many experts have suggested that
the effectiveness test of CPP treatment be performed at 2
different moments before and 60 minutes after the admin-
istration of leuprorelin (13-15,20).
The results of the present study showed that there is no
significant difference between the levels of LH collected 1 h
after the test and those collected after 2 h. Conversely, FSH
(and LH/FSH ratio) showed a significant difference at all test
moments, showing that FSH levels actually remain on the
Table 4 - Comparisons between the variables of the stimulation
test with LA, 3.75 mg IM, of the patients with CPP who showed
improvement of all assessed clinical parameters and the patients
in the control group.




Basal E2 (pmol/L) 18.36 (18.36; 18.65) 18.36 (18.36; 18.36) 0.633
Basal LH (IU/L) 0.10 (0.10; 0.10) 0.33 (0.17; 0.81) 0.005*
LH after 1 h (IU/L) 1.75 (1.03; 2.23) 3.09 (2.87; 3.45) 0.001*
LH after 2 h (IU/L) 2.10 (1.57; 2.76) 3.51 (2.74; 4.60) 0.004*
DLH (IU/L) 2.00 (1.13; 2.69) 3.23 (2.46; 3.64) 0.007*
Basal FSH (IU/L) 2.33 (0.82; 2.55) 1.49 (1.04; 1.94) 0.588
FSH after 1 h (IU/L) 9.80 (6.84; 10.61) 3.51 (2.99; 5.07) 0.006*
FSH after 2 h (IU/L) 15.30 (11.17; 15.72) 4.57 (2.90; 7.11) 0.002*
Basal LH/FSH 0.04 (0.04; 0.15) 0.24 (0.13; 0.44) 0.001*
LH/FSH after 1 h 0.21 (0.11; 0.26) 0.96 (0.55; 1.60) 0.001*
LH/FSH after 2 h 0.19 (0.10; 0.21) 0.70 (0.46; 1.13) 0.001*
Mann-Whitney test. P25: 25th percentile; P75: 75th percentile; h: hour;
*po0.05.
Table 3 - Evaluation of the effectiveness of PP treatment with a GnRH analog (3.75 mg, IM, every 28 days) according to clinical and
laboratory data of interest.
Case no Tanner (B) GV (cm/month) DBA-CA (months) FHP (cm) LH (IU/L)#
BT DT BT DT BT DT BT DT
1 2 2 0.58 0.50 27 38 151.9 148.8 4.6
2 3 3 0.60 0.46 34 34 148.9 150.0 4.64
3 3 3 0.70 0.60 37 25 143.9 152.0 5.54
4 2 2 1.30 0.38 35 39 148.7 149.8 9.65
5 3 3 0.56 0.48 42 32 156.6 163.2 6.1
6 2 1 0.25 0.66 22 25 133.1 136.4 6.74
7 3 3 0.95 0.80 -19 -12 157.5 158.3 6.96
8 4 2 0.86 0.40 47 41 152.1 155.0 5.16
9 2 2 0.82 0.44 27 40 153.6 150.8 3.58
10 3 3 0.90 0.92 14 22 163.4 164.2 54.48
11 3 1 0.77 0.63 32 21 146.5 152.6 2.83
12 2 1 0.50 0.12 31 27 150.4 151.0 4.43
13 2 1 0.60 0.50 14 19 159.3 157.5 9.98
14 4 3 0.66 0.36 30 29 160.1 161.1 80.14
15 3 3 0.63 0.20 36 20 152.5 156.4 2.66
16 3 3 0.53 0.28 28 25 154.5 158.0 3.8
17 1 2 0.80 0.77 1 28 165.1 150.5 4.11
18 3 3 0.50 0.50 23 15 152.5 158.3 3.44
19 3 1 0.85 0.15 19 8 155.0 158.2 3.32
20 2 1 1.10 0.38 53 87 149.8 133.1 7.97
21 3 1 0.75 0.57 13 30 166.2 157.2 2.97
22 2 3 1.50 0.60 33 30 151.2 157.3 7.0
23 3 1 0.76 0.40 17 19 144.0 140.9 0.9
24 2 1 0.60 0.36 8 4 163.2 164.7 1.24
Mean - - 0.75 0.48 25.2 26.9 153.3 153.6 10.09
SD - - 0.27 0.20 15.4 17.6 7.6 8.0 18.2
Minimum - - 0.25 0.12 -19 -12 133.1 133.1 0.9
Maximum - - 1.50 0.92 53 87 166.2 164.7 80.14
B: breast; BT: beginning of treatment; DT: during treatment; GV: growth velocity; DBA-CA: difference between bone age and chronological age; FHP: final
height prediction; #LH 2 h after GnRH analog treatment.
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rise for 2 h after leuprorelin administration, as demonstrated
by Bhatia et al. (21).
The pattern of FSH response during the acute GnRH and
the LH/FSH ratio of approximately 1 IU/L has been used by
some authors for CPP diagnosis, and in cases of gonado-
tropin-independent sexual precocity, FSH does not increase
significantly during the test, whereas its elevation is more
significant in CPP (31). To determine treatment effectiveness,
FSH measurement is also routinely performed during the test,
but there are no references for values that determine gona-
dotrophic axis suppression. FSH levels p5.43 IU/L after 1 h
of testing were indicative of pubertal suppression with
statistical significance, as were FSH levels p8.31 IU/L after
2 h of testing. Girls with good clinical control tended to have a
basal LH/FSH ratio p0.27; after 1 h, p2.02; and after 2 h,
p0.89.
To finalize the analysis of the variables measured during the
effectiveness test with LA, we assessed whether the values
obtained in patients with effective pubertal suppression were
equal to prepubertal values. To answer this question, the tests
performed in patients with clinical effectiveness were com-
pared with the tests of control patients, namely, those with
isolated precocious thelarche. Each variable measured by the
test was compared individually.
Except for basal estradiol and basal FSH, which showed
no difference between treatment-suppressed and control
patients, all other variables (basal LH, stimulated LH, DLH,
stimulated FSH and all moments of LH/FSH ratio) were
statistically higher in patients treated and suppressed with
LA. Thus, effective treatment did not recover the prepubertal
gonadotropin levels. Consequently, the cut-off values of
the variables obtained at LA testing differ in determining
the diagnosis of CPP and laboratory effectiveness of the
treatment.
This study has a main limitation, that is, the small sample
size that reduced the accuracy and reliability of cut-offs
recommended for monitoring treatment, and consequently,
studies with larger samples may yield different results. On
the other hand, its strength is to show that considering that
the test is performed in children, being fast and practical are
important qualities, and the collection of basal LH values
and LH values after 1 h of testing seems to be the best option.
In this case, values higher than 3.64 IU/L indicate treatment
adjustment. However, if it is decided to collect LH after 2 h of
testing, the cut-off value used is a different one (6.10 IU/L)
and similar to the findings of Brito et al. (12).
In conclusion, the LH response after an LA stimulation
test, associated with clinical data and within a context of
CPP, constitutes a reliable and feasible resource and can
assist in monitoring the effectiveness of treatment.
It is also possible to conclude that FSH measurement
aimed at evaluating treatment effectiveness is not necessary.
Finally, effective treatment with GnRHa does not reach the
prepubertal levels of stimulated LH.
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